Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
biotech
2
×
boston blog main
clinical trials
2
×
drugs
life sciences
national blog main
new york blog main
new york top stories
regeneron pharmaceuticals
rna interference
akcea therapeutics
alirocumab
amgen
barry greene
boston
boston top stories
boston university
dan ollendorf
evercore isi
evolocumab
fda
heart attack
hereditary transthyretin amyloidosis
inclisiran
inotersen
john berk
joseph swartz
mary o'donnell
medicines co.
national top stories
new york
patisiran
pcsk9 inhibitors
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
stroke
svb leerink
What
alnylam
2
×
rna
ago
approve
awaits
based
biological
cholesterol
crossed
data
decades
decision
discovered
drug
evidence
fda
fingers
friday
heart
historic
lasting
long
looms
lowering
medco
medicine
medicines
new
partner
patients
pharmaceuticals
presented
reckoning
supporting
term
time
touts
trick
use
uses
Language
Current search:
alnylam
×
biotech
×
" clinical trials "
×
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision